CACCESE, MARIO

CACCESE, MARIO  

Università di Padova  

Mostra records
Risultati 1 - 20 di 25 (tempo di esecuzione: 0.051 secondi).
Titolo Data di pubblicazione Autori Rivista Serie Titolo libro
A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib 2021 Santangelo A.Indraccolo S.Prandini P.DI Gennaro G.Caccese M.Zagonel V. + NEURO-ONCOLOGY - -
Advanced Adrenocortical Carcinoma: From Symptoms Control to Palliative Care 2022 Ruggiero, ElenaTizianel, IreneCaccese, MarioLombardi, GiuseppePambuku, ArdiZagonel, VittorinaScaroni, CarlaCeccato, Filippo + CANCERS - -
Anaplastic Astrocytoma: State of the art and future directions 2020 Caccese M.Padovan M.D'Avella D.Gardiman M. P.Fassan M.Zagonel V. + CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY - -
Association between thyroid function and regorafenib efficacy in patients with relapsed wild-type IDH glioblastoma: a large multicenter study 2023 Caccese M.Bruno F.Cerretti G.Denaro L.Lombardi G. + JOURNAL OF NEURO-ONCOLOGY - -
Case report: The lesson from opioid withdrawal symptoms mimicking paraganglioma recurrence during opioid deprescribing in cancer pain 2023 Caccese, MarioCeccato, Filippo + FRONTIERS IN PAIN RESEARCH - -
Clinical management of diffuse low-grade gliomas 2020 Castellano A.Salvalaggio A.Cerretti G.Caccese M.Padovan M.Zagonel V. + CANCERS - -
Comparison between18F-Dopa and 18F-Fet PET/CT in patients with suspicious recurrent high grade glioma: A literature review and our experience 2019 Evangelista L.Cuppari L.Bellu L.Caccese M.Zagonel V.Lombardi G. + CURRENT RADIOPHARMACEUTICALS - -
Corneal side effects induced by EGFR-inhibitor antibody–drug conjugate ABT-414 in patients with recurrent glioblastoma: a prospective clinical and confocal microscopy study 2020 Parrozzani, RaffaeleLombardi, GiuseppeMidena, EdoardoLeonardi, FrancescaLondei, DavidePadovan, MartaCaccese, MarioMarchione, GiuliaBini, SilviaZagonel, VittorinaFrizziero, Luisa THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY - -
Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter Study 2022 Mario CacceseLuisa BelluFrancesco CavallinMatteo FassanVittorina ZagonelLombardi Giuseppe + CANCERS - -
Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study 2021 Guarneri V.Zagonel V.Milella M.Cattelan A. M.Vianello A.Gori S.Aprile G.Oliani C.Bernardi D.Morandi P.Toso S.Di Liso E.Caccese M.Puccetti O.Celestino M.Dieci M. V.Conte P. + EUROPEAN JOURNAL OF CANCER - -
Good tolerability of maintenance temozolomide in glioblastoma patients after severe hematological toxicity during concomitant radiotherapy and temozolomide treatment: report of two cases 2018 Lombardi, GiuseppeCACCESE, MARIOBellu, LuisaPambuku, ArdiBerti, FrancoGardiman, Marina PDenaro, LucaZagonel, Vittorina + ANTI-CANCER DRUGS - -
Impressive response to dabrafenib and trametinib plus silybin in a heavily pretreated IDH wild-type glioblastoma patient with BRAFV600E-mutant and SOX2 amplification 2022 Cerretti, GiuliaCecchin, DiegoDenaro, LucaCaccese, MarioPadovan, MartaZagonel, VittorinaLombardi, Giuseppe ANTI-CANCER DRUGS - -
Knowing when to discontinue Temozolomide therapy in responding aggressive pituitary tumors and carcinomas: a systematic review and Padua (Italy) case series 2023 Padovan M.Cerretti G.Caccese M.Barbot M.Occhi G.Scaroni C.Lombardi G.Ceccato F. + EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM - -
Letter to Editor: Reply to R.T. Casey (Semin Oncol. 2018 Jun;45(3):151-155) 2019 Caccese, MarioFassan, MatteoFassina, AmbrogioPADOVAN, MARTAIacobone, MaurizioScaroni, CarlaZagonel, VittorinaLombardi, GiuseppeCECCATO, FILIPPO + SEMINARS IN ONCOLOGY - -
Metronomic Temozolomide in Heavily Pretreated Patients With Recurrent Isocitrate Dehydrogenase Wild-type Glioblastoma: A Large Real-Life Mono-Institutional Study 2023 Cerretti, GPadovan, MCaccese, MDenaro, LGuarneri, VLombardi, G + CLINICAL ONCOLOGY - -
Mismatch-repair protein expression in high-grade gliomas: A large retrospective multicenter study 2020 Caccese M.Fassan M.Cavallin F.Padovan M.Salvalaggio A.Gardiman M. P.Zagonel V. + INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES - -
Ocular Side Effects of EGFR-Inhibitor ABT-414 in Recurrent Glioblastoma: A Long-Term Safety Study 2020 Parrozzani R.Midena E.Londei D.Padovan M.Marchione G.Caccese M.Midena G.Zagonel V.Frizziero L. + FRONTIERS IN ONCOLOGY - -
PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review 2019 Caccese M.Indraccolo S.Zagonel V. + CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY - -
Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study 2020 Lombardi, GiuseppeIndraccolo, StefanoFassan, MatteoMandruzzato, SusannaCaccese, MarioPizzi, MarcoPadovan, MartaMasetto, ElenaGardiman, Marina PaolaDenaro, LucaDei Tos, Angelo PaoloScarpa, AldoZagonel, Vittorina + CANCERS - -
PET/MR in recurrent glioblastoma patients treated with regorafenib: [18F]FET and DWI-ADC for response assessment and survival prediction 2022 Spimpolo A.Berti S.Evangelista L.Causin F.Zorzi G.Caccese M.Padovan M.Zagonel V.Cecchin D. + BRITISH JOURNAL OF RADIOLOGY - -